Search intent for this topic wants a yes or no answer. The workable answer is a boundary map: a strong black box or boxed warning in the China label helps a warning defence, but it does not erase manufacturing defects, delayed label updates, off-label promotion or product design failures. This article explains what a boxed warning actually buys a drug manufacturer under PRC tort law, what it does not buy, and how pharmacovigilance and legal teams should document warning decisions so the file survives scrutiny.
The warning defence in PRC product liability
China's product liability regime for drugs is strict liability built on the Civil Code, supplemented by the Drug Administration Law and the NMPA labeling rules. The strict liability framework means that a manufacturer can be liable for a defective product without proof of negligence in the traditional sense. The practical question for the warning defence is therefore not whether the company was careful, but whether the product itself was defective, and whether the warning that accompanied the product was sufficient to make the product's risk reasonably safe for its intended use. A boxed warning that clearly communicates a known serious risk is evidence that the manufacturer did not hide the risk; it is not a shield against claims that the product was defective for reasons unrelated to the warned risk.
The boundary matters because in-house teams often over-read the label. The presence of a strong warning does not convert an otherwise defective product into a safe one. If the batch fails quality standards, if the design is flawed, or if the label lags behind a newly identified serious signal, the warning defence collapses even though the box is black. The disciplined approach is to treat the label as one component of the defence file, not as the defence itself.
Statutory framework
Civil Code tort provisions
The PRC Civil Code, in Book Seven on Tort Liability, establishes the framework for drug product liability. Article 1202 provides that where a product is defective and causes damage to another person, the manufacturer is liable. Article 1203 gives the injured party the option to claim against the manufacturer or the seller, and allows the seller to recover from the manufacturer after paying. Article 1206 requires that where a defect is discovered after the product is put into circulation, the manufacturer and seller shall take remedial measures including warning, recall or other relief, and provides that where the remedial measures are not timely or are insufficient, the parties are liable for the resulting damage. The warning defence is therefore anchored in Article 1206: the company must show that its warning was timely, sufficient and maintained after the risk was discovered.
"Article 1206 of the PRC Civil Code: Where a defect is discovered after a product has been put into circulation, the manufacturer or seller shall take remedial measures in a timely manner, such as issuing a warning, recalling the product or taking other relief measures."
Drug Administration Law and labeling rules
The PRC Drug Administration Law Article 49 requires that drug package inserts and labels comply with the requirements of the NMPA, and that the contents be truthful, accurate and consistent with the approved registration. The NMPA Provisions on Drug Insert and Label Management, Article 11, requires that special warnings for serious adverse reactions be highlighted, which is the basis for the boxed or black box warning format in the China label. The combination of these provisions means that the warning is not merely a commercial communication; it is a regulatory obligation with a defined format and a defined approval path, and the company's compliance with the format is itself evidence in a tort case.
What a strong warning actually buys you
In practice, a well-documented boxed warning provides three benefits. First, it is evidence that the known serious risk was communicated in the China label at the relevant time, which undercuts a plaintiff's narrative that the company concealed the risk. Second, it supports the defence against a pure failure-to-warn theory, because the plaintiff must show not merely that the risk existed but that the warning was insufficient in content or timing; a boxed warning that names the specific adverse outcome and its management substantially narrows that argument. Third, it provides the framework for health care professional communications, because the company can show that its medical information activities were consistent with the label rather than contrary to it. Each of these benefits depends on the warning being current, specific and actually used in the company's communications, not merely present in the filing cabinet.
What it does not buy you
The boundary map also identifies the four claims that a boxed warning does not answer. First, a warning does not immunize lot-quality or design defects unrelated to the warned risk; a manufacturing deviation that produces a contaminated batch is a defect regardless of the label. Second, a warning does not protect promotion that minimizes the boxed risk; if medical representatives or MSL scripts describe the risk as minor, the company has undermined the very communication that the defence relies on. Third, a warning does not cover delayed updates; if the global core data sheet moved and the China label lagged without a documented decision, the silence in the file becomes the plaintiff's best argument. Fourth, a warning does not excuse off-label promotion; a company that profits from an unapproved indication cannot rely on a label that never mentioned the indication.
- Analytical diagram of the PRC warning defence. A strong NMPA boxed warning supports three failure-to-warn benefits, but leaves four claim types open: manufacturing or design defects, risk-minimizing promotion, delayed label updates, and off-label promotion. The centre states that a black box is not automatic immunity.
- Boundary map: what a China boxed warning buys and does not buy under product liability.
- Civil Code Arts. 1202 / 1206 · Drug Administration Law Art. 49 · NMPA insert rules · SPC Guiding Case No. 80
- Strong black box / boxed warning
- Evidence of risk communication — not a shield
Enforcement context: SPC Guiding Case No. 80
The Supreme People's Court Guiding Case No. 80 addresses the warning duty in the medical context and the limits of label compliance. The case reaffirmed that while a manufacturer that fulfills basic warning duties through NMPA-approved labels has taken a relevant step, liability remains where the warning fails to clearly state the specific, preventable adverse consequences or the counter-measures the patient or physician should take. The guiding case is important because it converts the warning defence from a formal check to a substantive test: the label must do more than exist, it must communicate in a way that enables the user to avoid the harm. This is the same logic that courts in other jurisdictions apply, and it is the logic that in-house teams should use when deciding whether a boxed warning is adequate or merely present.
Enforcement context: the label update and PV record discipline
The pharmacovigilance interface is where the warning defence is won or lost. Every serious signal review should end with a written label decision: update, watch or no action, with the owner, the date and the basis. The decision record should capture the signal, the evidence reviewed, the options considered and the chosen action. Where the decision is update, the record should track the regulatory submission timeline. Where the decision is no action, the record should explain why the signal was not label-relevant, so that a later plaintiff or inspector cannot argue that the risk was ignored. The same discipline applies to the global versus China label gap: when the company core data sheet moves and the China label does not, the file must contain the decision to defer, the analysis of the China-specific regulatory basis and the planned update date. Silence is what plaintiffs and inspectors read as delay.
- Flow chart from serious safety signal identification through evidence review to label decisions of update, watch, or no action, including China–global CDS gap handling and HCP communication consistency checks that preserve the warning defence.
- Article 1206 pharmacovigilance and label decision flow for China boxed warnings.
- Every serious signal ends with a written decision: update · watch · no action — silence is delay
- Serious signal identified
- ADR cluster, literature, global CDS,
The black box warning defence and PV record template
The practical deliverable is a decision log that integrates the pharmacovigilance, regulatory affairs and legal functions. The template has five fields for each entry: the signal or event reviewed; the date the signal was identified; the evidence and sources considered; the label decision with owner and date; and the follow-up actions with deadlines. The log should be maintained in the company's document management system, with access restricted to the designated functions, and should be referenced in the annual safety report and any regulatory inspection response. In litigation, the log becomes the company's contemporaneous record that it performed the Article 1206 remedial analysis, that the warning was timely and sufficient, and that any delay was documented and justified.
The log is also the tool that protects the company in the most common failure scenario: the plaintiff claims the company knew or should have known of a risk and did nothing. A complete log showing the signal was assessed, the decision was made and the action was executed defeats that narrative. An empty log, or a log with gaps during the critical period, creates the inference of concealment even where no concealment occurred. The discipline is simple: if it is not in the log, it did not happen.
Companies should also prepare the warning defence for the HCP communication angle. If the boxed warning is the centre of the defence, then every medical science liaison slide, every sales training deck and every field question-and-answer script must treat the warning as a boundary, not an inconvenience. A defence that rests on a strong label is destroyed by a single internal document that tells representatives the boxed warning is overstated or that physicians will not read it. The compliance function should periodically audit the field materials for statements that minimize the warned risk, and should quarantine any material that contradicts the label. This audit is not only a regulatory control; it is the preservation of the tort defence. The same audit should cover the company's response to unsolicited medical information requests, because an answer that speculates beyond the label creates the same inconsistency as an aggressive promotional claim. By keeping every outward-facing communication traceable to the approved label, the company ensures that the boxed warning it relies on in litigation is the same warning the market actually received.
Read next: Drug labeling, ADR & warnings · Pharma advertising
Discussion
Share experience or questions about this topic. This is a public discussion — not legal advice. Do not post confidential case details.
Have a question after reading? Leave it here, or Ask a Lawyer for a free initial consultation.
Comments are moderated. China Legal Portal is a directory and information resource; no attorney–client relationship is formed by posting here.
